Most sites undercharge on research-paid items because no one reconciles the sponsor budget against the charge master. Here is ...
Forward Therapeutics' FT2109 advances to Phase 2 after clearing Phase 1 with once-daily oral dosing and a supportive safety ...
Headlands Research Portland site marks 50 years of continuous Alzheimer's trials, contributing to every FDA-approved ...
Advarra's IRB chief targets pre-review delays as the next efficiency frontier to reduce waiting time for researchers and trial participants.
Jon Himoff, Chief Product Officer of Image Analysis Group (IAG), on why purpose-built imaging platforms outperform assembled ...
A pilot RCT links psilocybin's 25 mg dose to reduced egocentric bias in alcohol use disorder, exposing a blind spot in how ...
First-in-human trial targets the amygdala with focused ultrasound in MDD, raising hard questions about biomarker selection, ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results